GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Buy GILD
up 443.75 %

Gilead Sciences, Inc. (GILD) rated Buy

Posted on: Friday,  Jul 20, 2007  9:25 AM ET by CIBC Wrld Mkts

CIBC Wrld Mkts rated Buy Gilead Sciences, Inc. (NASDAQ: GILD) on 07/20/2007, when the stock price was $19.86.
Since then, Gilead Sciences, Inc. has gained 443.76% as of 10/28/2015's recent price of $107.99.
If you would have followed this CIBC Wrld Mkts's recommendation on GILD, you would have gained 443.75% of your investment in 3022 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

CIBC World Markets strives to deliver leading edge investment research to investing clients through our multi-faceted, firm-wide research product offering. Our research has consistently been recognized as a top research source for its breadth of coverage, industry knowledge and quality of work in generating profitable and timely investment ideas. We provide in-depth coverage for all of the major sectors of the Canadian economy and select coverage of U.S. companies. Our analytical teams remain committed to identifying trends early and developing exploitable investment opportunities across the market capitalization spectrum. With the continued growth in quantitative and computerized investing strategies, we have also developed leading edge quantitative and technical research products to partner with our fundamental approach. Our products are available through several automated avenues: email, website, and third-party market vendors. Client service is our driving force and we constantly advance in offering greater product customization options.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/20/2007 9:25 AM Buy
None
19.86 22.50
as of 8/27/2015
1 Week down  -5.63 %
1 Month down  -11.63 %
3 Months down  -0.68 %
1 YTD up  43.79 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy